Figure 4From: Development of a new pre-vascularized tissue-engineered construct using pre-differentiated rADSCs, arteriovenous vascular bundle and porous nano-hydroxyapatide-polyamide 66 scaffold Flow cytometry analysis of rADSCs. P3 rADSCs are CD34 and CD45 negative (B and D), but CD29 and CD44 positive (A and C).Back to article page
